The abuse of amphetamine and its congeners continues to plaque society; indeed, some indicators suggest that amphetamine abuse is increasing. Significant advances have been made in characterizing the effects of methamphetamine (METH) on brain neurochemistry. Large doses of METH decrease activity of the brain biogenic amine synthetic enzymes, tyrosine hydroxylase and tryptophan hydroxylase, as well as concentrations of dopamine and 5-hydroxytryptamine and their metabolites. These changes are accompanied by dramatic alterations in selected brain neuropeptide systems. Although significant progress has been made, additional studies are indicated to elucidate the mechanism(s) responsible for these effects. Results from preliminary studies strongly that glutamate and calcium contribute to METH-medicated neurochemical alterations. Because manipulation of these systems may lead to important new treatments for amphetamine abuse and toxicity, the role of glutamate and calcium in METH- induced effects will be investigated. The significance of the substantial neuropeptide changes observed after METH will be extensively studied. The increasing public health problem of drug abuse during pregnancy prompted the proposed study to determine whether the marked neurochemical changes observed in adult rats also occur in the offspring exposed in utero to METH. Since the incidence of smoking crystalline METH appears to be increasing, especially in the western United States, neurochemical responses observed when METH is administration. The inhalation will be compared with those occurring after parenteral administration. The procedures employed to determine the activity of biosynthetic enzymes, concentrations of neurotransmitters and their metabolites, neuropeptide levels and drug concentrations in various brain regions are techniques which are routinely utilized in our laboratories. The results of these studies will provide additional information about the interrelationships between neuropeptide, biogenic amine and excitatory amino acid systems within the brain. Moreover, a better understanding of the mechanisms responsible for the neurochemical changes observed after METH will hopefully lead to improved treatment strategies for amphetamine abuse and toxicity. These findings will also hopefully provide improved understanding and better therapy for neurological dysfunctions related to parkinsonism, brain ischemia and psychotic illness.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA000869-18
Application #
2116407
Study Section
Drug Abuse Biomedical Research Review Committee (DABR)
Program Officer
Lin, Geraline
Project Start
1973-11-01
Project End
1993-12-31
Budget Start
1992-07-15
Budget End
1993-12-31
Support Year
18
Fiscal Year
1992
Total Cost
Indirect Cost
Name
University of Utah
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
City
Salt Lake City
State
UT
Country
United States
Zip Code
84112
Fricks-Gleason, Ashley N; German, Christopher L; Hoonakker, Amanda J et al. (2016) An acute, epitope-specific modification in the dopamine transporter associated with methamphetamine-induced neurotoxicity. Synapse 70:139-46
McFadden, Lisa M; Vieira-Brock, Paula L; Hanson, Glen R et al. (2015) Prior methamphetamine self-administration attenuates the dopaminergic deficits caused by a subsequent methamphetamine exposure. Neuropharmacology 93:146-54
Baladi, Michelle G; Newman, Amy H; Nielsen, Shannon M et al. (2014) Dopamine D(3) receptors contribute to methamphetamine-induced alterations in dopaminergic neuronal function: role of hyperthermia. Eur J Pharmacol 732:105-10
German, Christopher L; Fleckenstein, Annette E; Hanson, Glen R (2014) Bath salts and synthetic cathinones: an emerging designer drug phenomenon. Life Sci 97:2-8
Baladi, Michelle G; Nielsen, Shannon M; Umpierre, Anthony et al. (2014) Prior methylphenidate self-administration alters the subsequent reinforcing effects of methamphetamine in rats. Behav Pharmacol 25:758-65
McFadden, Lisa M; Stout, Kristen A; Vieira-Brock, Paula L et al. (2012) Methamphetamine self-administration acutely decreases monoaminergic transporter function. Synapse 66:240-5
McFadden, Lisa M; Hunt, Madison M; Vieira-Brock, Paula L et al. (2012) Prior methamphetamine self-administration attenuates serotonergic deficits induced by subsequent high-dose methamphetamine administrations. Drug Alcohol Depend 126:87-94
McFadden, Lisa M; Hadlock, Greg C; Allen, Scott C et al. (2012) Methamphetamine self-administration causes persistent striatal dopaminergic alterations and mitigates the deficits caused by a subsequent methamphetamine exposure. J Pharmacol Exp Ther 340:295-303
German, Christopher L; Hanson, Glen R; Fleckenstein, Annette E (2012) Amphetamine and methamphetamine reduce striatal dopamine transporter function without concurrent dopamine transporter relocalization. J Neurochem 123:288-97
Hadlock, Gregory C; Nelson, Chad C; Baucum 2nd, Anthony J et al. (2011) Ex vivo identification of protein-protein interactions involving the dopamine transporter. J Neurosci Methods 196:303-7

Showing the most recent 10 out of 162 publications